Forum
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis
Authors' affiliations
Quarraisha Abdool Karim, 1) CAPRISA, Durban, 2) Department of Public Health and Family Medicine, University of KwaZulu-Natal, Durban, 3) Department of Epidemiology, Mailman School of Public Health at Columbia University
Salim S Abdool Karim, 1) CAPRISA, Durban, 2) Department of Public Health and Family Medicine, University of KwaZulu-Natal, Durban, 3) Department of Epidemiology, Mailman School of Public Health at Columbia University
Cheryl Baxter, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Gerald Friedland, Yale University School of Medicine, New Haven
Tanuja Gengiah, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Andrew Gray, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Anneke Grobler, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Kogileum Naidoo, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Nesri Padayatchi, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban
Wafaa El-Sadr, 1) Department of Epidemiology, Mailman School of Public Health at Columbia University, New York, Department of Internal Medicine and Epidemiology, Yale University School of Medicine, New Haven, 2) International Center for AIDS Care and Treatment Programs
Full Text
PDF (71KB)Keywords
Cite this article
Article History
Date published: 2010-12-01
Article Views
Full text views: 1283
Comments on this article
*Read our policy for posting comments here